New MRI contrast agent detects invasive lung cancer earlier

Researchers have developed a novel protein-based MRI contrast agent that can detect invasive lung cancer at earlier stages than traditional imaging methods. This precision MRI technique can identify tumors as small as 1 millimeter, including metastases, without exposing patients to radiation. The technology, known as hProCA32.Collagen, targets collagen type I, a protein found at higher levels in aggressive lung tumors and metastatic lesions.

In preclinical studies, the agent successfully detected and quantified small lung tumors in the lungs, adrenal glands, and kidneys while mapping biological features linked to tumor invasion. The research, partially funded by the National Institutes of Health, was a collaborative effort between Georgia State University, Emory University, and other institutions.

The findings potentially offer personalized cancer treatment by enabling physicians to monitor treatment response and identify high-risk patients. InLighta Biosciences, a biotech company founded by Jenny J. Yang, is working to advance the technology toward clinical use.